In order to guide enterprises to operate with integrity and compliance and further promote the healthy development of the centralized pharmaceutical procurement market, the National Healthcare Security Administration recently issued the "Notice on Further Improving the Pharmaceutical Price and Procurement Credit Evaluation System" to revise the pharmaceutical price and procurement credit evaluation system.

In August 2020, the National Healthcare Security Administration issued the Guiding Opinions on Establishing a Credit Evaluation System for Pharmaceutical Prices and Procurement, and carried out credit rating, graded disposal, credit repair and other work based on the facts of cases such as drug sales with money and bid rigging determined by court judgments or administrative penalties. By the end of 2024, 735 untrustworthy enterprises were assessed, including 7 "particularly serious" untrustworthy enterprises, 40 "serious" untrustworthy enterprises, 76 "medium" untrustworthy enterprises, and 612 "general" untrustworthy enterprises.

The implementation of this system has played a positive role in curbing commercial bribery, sales with bonuses and other behaviors in the field of medical procurement and sales, and in creating a fair, standardized and clean medical procurement environment.

This revision, while adhering to the original system framework, has made adjustments to the evaluation levels and basis: First, on the basis of the original court judgments and punishment decisions of relevant law enforcement administrative departments, audit reports, audit information, audit transfer and processing documents and other case source information have been added. Second, the four levels of dishonesty, "general", "medium", "serious" and "particularly serious", have been adjusted to three levels of "dishonesty", "serious dishonesty" and "particularly serious dishonesty", and the evaluation standards have been adjusted accordingly. Third, the punishment has been precisely increased. For dishonest behavior involving bribery of medical security department (including centralized pharmaceutical procurement agencies) staff, or enterprises that collude in bidding in the centralized volume procurement organized by the state, they will all be dealt with as "particularly serious dishonesty". For "particularly serious dishonest" production enterprises, while suspending the listing and bidding qualifications of all their products in the evaluated provinces, the listing and bidding qualifications of the products involved in the case in all provinces will also be suspended. Fourth, the relevant procedures will be improved. Further improve the corrective measures for dishonest behavior, encourage enterprises to correct through price reduction, and no longer retain the method of charitable donations.

https://finance.eastmoney.com/a/202506063423276223.html